Drug-induced QT interval prolongation: Do we know the risks?

被引:1
|
作者
Villamanan, Elena [1 ]
Armada, Eduardo [2 ]
Ruano, Margarita [1 ]
机构
[1] Hosp Univ La Paz, Serv Farm, Madrid, Spain
[2] Hosp Univ La Paz, Serv Cardiol, Madrid, Spain
来源
MEDICINA CLINICA | 2015年 / 144卷 / 06期
关键词
QT interval prolongation; Torsade de pointes; Drugs; Risk factors; Drug interactions; SUDDEN CARDIAC DEATH; TORSADE-DE-POINTES; ORAL ERYTHROMYCIN; MACROLIDE;
D O I
10.1016/j.medcli.2014.01.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Sudden cardiac death is an important cause of mortality in developed countries, most of them being consequence of acute ventricular arrhythmias. These arrhythmias, in some cases, owe to QT interval prolongation. A major risk factor for this condition is the use of drugs that prolong the QT interval. In fact, in recent years, one of the most common reasons for drug withdrawal or usage restrictions has been drug induced QT interval prolongation that involves both cardiovascular and non-cardiovascular drugs. Taking into account the severity that the occurrence of such an event may have, it is important for clinicians to know the risks of these drugs in certain patients. In this review we analyze the drugs that prolong the QT interval, the risk factors that can enhance QT prolongation and the drug interactions that can increase these risks. (C) 2013 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:269 / 274
页数:6
相关论文
共 50 条
  • [31] Papaverine-induced QT Interval Prolongation and Ventricular Fibrillation in a Patient with a History of Drug-induced QT Prolongation
    Goto, Masayuki
    Sato, Masahito
    Kitazawa, Hitoshi
    Takahashi, Minoru
    Fuse, Koichi
    Saito, Atsushi
    Okabe, Masaaki
    Aizawa, Yoshifusa
    INTERNAL MEDICINE, 2014, 53 (15) : 1629 - 1631
  • [32] Evaluation of drug-induced QT interval prolongation - Implications for drug approval and labelling
    Malik, M
    Camm, AJ
    DRUG SAFETY, 2001, 24 (05) : 323 - 351
  • [33] Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation
    Coi, Alessio
    Massarelli, Ilaria
    Testai, Lara
    Calderone, Vincenzo
    Bianucci, Anna Maria
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (11) : 2479 - 2488
  • [34] Drug-Induced QT Interval Prolongation: Clinical, Safety and Regulatory Update
    Di Girolamo, Guillermo
    CURRENT DRUG SAFETY, 2010, 5 (01) : 41 - 43
  • [35] A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation
    Simon, Steven T.
    Lin, Meng
    Trinkley, Katy E.
    Aleong, Ryan
    Rafaels, Nicholas
    Crooks, Kristy R.
    Reiter, Michael J.
    Gignoux, Christopher R.
    Rosenberg, Michael A.
    PLOS ONE, 2024, 19 (06):
  • [36] Prediction of drug-induced QT interval prolongation in telemetered common marmosets
    Tabo, Mitsuyasu
    Hara, Toshiko
    Sone, Sachiko
    Shishido, Nobuyuki
    Kuramoto, Shino
    Nakano, Kounosuke
    Onodera, Hideko
    Kimura, Kazuya
    Kobayashi, Kazuko
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2008, 33 (03): : 315 - 325
  • [37] Evaluation of the QT interval in patients with drug-induced QT prolongation and torsades de pointes
    Krisai, Philipp
    Vlachos, Konstantinos
    Ramirez, F. Daniel
    Nakatani, Yosuke
    Nakashima, Takashi
    Takagi, Takamitsu
    Kamakura, Tsukasa
    Surget, Elodie
    Andre, Clementine
    Cheniti, Ghassen
    Welte, Nicolas
    Chauvel, Remi
    Tixier, Romain
    Duchateau, Josselin
    Pambrun, Thomas
    Derval, Nicolas
    Hocini, Meleze
    Jais, Pierre
    Hassaguerre, Michel
    Sacher, Frederic
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2020, 31 (10) : 2696 - 2701
  • [38] Drug-induced QT prolongation: An update
    Moss, AJ
    ANNALS OF NONINVASIVE ELECTROCARDIOLOGY, 2006, 11 (01) : 1 - 2
  • [40] Drug-Induced QTc Prolongation: What We Know and Where We Are Going
    Mangona, Erinn
    Sandonato, Elisa
    Brothers, Todd N.
    Pawasauskas, Jayne
    CURRENT DRUG SAFETY, 2022, 17 (02) : 100 - 113